Hinova Pharmaceuticals Inc. (SHA:688302)
China flag China · Delayed Price · Currency is CNY
40.32
-0.38 (-0.93%)
At close: Mar 30, 2026

Hinova Pharmaceuticals Ratios and Metrics

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
3,9924,8693,0415,1563,992-
Market Cap Growth
19.96%60.11%-41.02%29.14%--
Enterprise Value
3,1824,0582,1413,9912,299-
Last Close Price
40.3249.1730.7152.0740.32-
PS Ratio
193.11235.508289.18-2418.38-
PB Ratio
3.634.422.553.772.52-
P/TBV Ratio
3.734.552.623.862.57-
EV/Sales Ratio
153.91196.305837.54-1392.58-
Debt / Equity Ratio
0.100.100.010.010.020.01
Net Debt / Equity Ratio
-0.74-0.74-0.70-0.80-0.97-1.14
Net Debt / EBITDA Ratio
6.066.063.703.264.432.62
Net Debt / FCF Ratio
--3.023.083.993.62
Asset Turnover
--0-0.00-
Inventory Turnover
--66.31-134.51-
Quick Ratio
--5.7510.3411.354.71
Current Ratio
--6.0310.7411.654.99
Return on Equity (ROE)
-11.92%-11.92%-15.59%-19.93%-25.40%-34.50%
Return on Assets (ROA)
---9.98%-13.04%-16.00%-19.89%
Return on Capital Employed (ROCE)
---18.80%-24.30%-21.80%-43.60%
Earnings Yield
-3.42%-2.81%-6.56%-5.71%-7.55%-
FCF Yield
---9.10%-6.88%-9.62%-
Buyback Yield / Dilution
0.20%0.20%-0.21%-9.06%-22.21%-5.74%
Source: S&P Global Market Intelligence. Standard template. Financial Sources.